Nader Pourhassan, CytoDyn CEO (Photo by Jeff Kravitz/FilmMagic for CytoDyn’s Pro)
August 3, 2021 07:22 AM EDTUpdated 08:31 AM
R&D

Cy­to­Dyn faces DOJ, SEC sub­poe­nas af­ter pro­mot­ing failed Covid-19 drug

Jason Mast

Editor

The lit­tle, PR-hap­py drug com­pa­ny pub­licly called out by the FDA is now get­ting at­ten­tion from both the SEC and the De­part­ment of Jus­tice. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times